Tags

Type your tag names separated by a space and hit enter

Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
AIDS Res Hum Retroviruses. 2019 02; 35(2):150-154.AR

Abstract

Access to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) for HIV has been increasing in Peru since a national ART program was initiated in 2004. Between 2007 and 2009, we found a 1% prevalence of pre-ART HIV drug resistance (PDR) among antiretroviral (ARV)-naive Peruvians. Given that PDR has been associated with virologic failure (VF) of ART, in 2014-2015 we enrolled a follow-up cohort at the same institution to determine whether the rate of transmitted resistance had increased and compared virologic outcomes of those with and without PDR. Blood specimens from ARV-naive individuals were assessed for PDR to NNRTI-based ART by an oligonucleotide ligation assay (OLA) sensitive to 2% mutant within an individual's HIV quasispecies at reverse transcriptase codons M41L, K65R, K103N, Y181C, M184V, and G190A, and by Sanger consensus sequencing (CS). Rates of VF (plasma HIV RNA >200 copies/mL) were compared between those with and without PDR. Among 122 ARV-naive adults, PDR was detected by OLA in 17 (13.9%) adults. Compared with the 2007-2009 cohort, the proportion with PDR at OLA codons was significantly increased (p < .001). A total of 11 of 19 OLA mutations conferring high-level drug resistance were also detected by CS, and 8 additional participants had mutations encoding low-level resistance detected by CS for a total of 25 participants (20.5%). VF at month 6 of NNRTI-ART appeared greater in participants with versus without PDR [4/18 (22.2%) vs. 3/71 (4.2%); p = .03]. An increasing prevalence of PDR was detected among ARV-naive Peruvians. Studies are needed to determine risks of specific PDR mutations.

Authors+Show Affiliations

1 Infectious and Tropical Diseases Department. Hospital Nacional Dos de Mayo, Lima, Peru. 2 Northern Pacific Global Health Research Fellows Training Consortium, University of Washington, Seattle, Washington.1 Infectious and Tropical Diseases Department. Hospital Nacional Dos de Mayo, Lima, Peru.3 Center for Global Infectious Diseases Research, Seattle Children's Research Institute, Seattle, Washington.4 Socios en Salud Sucursal del Peru, Lima, Peru.1 Infectious and Tropical Diseases Department. Hospital Nacional Dos de Mayo, Lima, Peru.1 Infectious and Tropical Diseases Department. Hospital Nacional Dos de Mayo, Lima, Peru. 5 Faculty of Medicine. Universidad Nacional Mayor de San Marcos, Lima, Peru.3 Center for Global Infectious Diseases Research, Seattle Children's Research Institute, Seattle, Washington.3 Center for Global Infectious Diseases Research, Seattle Children's Research Institute, Seattle, Washington. 6 Department of Pediatric, University of Washington, Seattle, Washington. 7 Department of Laboratory Medicine, University of Washington, Seattle, Washington. 8 Department of Global Health, University of Washington, Seattle, Washington. 9 Department of Medicine, University of Washington, Seattle, Washington.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30560685

Citation

Soria, Jaime, et al. "Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru." AIDS Research and Human Retroviruses, vol. 35, no. 2, 2019, pp. 150-154.
Soria J, Mugruza R, Levine M, et al. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru. AIDS Res Hum Retroviruses. 2019;35(2):150-154.
Soria, J., Mugruza, R., Levine, M., León, S. R., Arévalo, J., Ticona, E., Beck, I. A., & Frenkel, L. M. (2019). Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru. AIDS Research and Human Retroviruses, 35(2), 150-154. https://doi.org/10.1089/AID.2018.0239
Soria J, et al. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru. AIDS Res Hum Retroviruses. 2019;35(2):150-154. PubMed PMID: 30560685.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru. AU - Soria,Jaime, AU - Mugruza,Raquel, AU - Levine,Molly, AU - León,Segundo R, AU - Arévalo,Jorge, AU - Ticona,Eduardo, AU - Beck,Ingrid A, AU - Frenkel,Lisa M, Y1 - 2019/01/22/ PY - 2018/12/19/pubmed PY - 2020/2/13/medline PY - 2018/12/19/entrez KW - HIV KW - Peru KW - antiretroviral-naive KW - oligonucleotide ligation assay KW - pre-ART HIV drug resistant SP - 150 EP - 154 JF - AIDS research and human retroviruses JO - AIDS Res. Hum. Retroviruses VL - 35 IS - 2 N2 - Access to nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) for HIV has been increasing in Peru since a national ART program was initiated in 2004. Between 2007 and 2009, we found a 1% prevalence of pre-ART HIV drug resistance (PDR) among antiretroviral (ARV)-naive Peruvians. Given that PDR has been associated with virologic failure (VF) of ART, in 2014-2015 we enrolled a follow-up cohort at the same institution to determine whether the rate of transmitted resistance had increased and compared virologic outcomes of those with and without PDR. Blood specimens from ARV-naive individuals were assessed for PDR to NNRTI-based ART by an oligonucleotide ligation assay (OLA) sensitive to 2% mutant within an individual's HIV quasispecies at reverse transcriptase codons M41L, K65R, K103N, Y181C, M184V, and G190A, and by Sanger consensus sequencing (CS). Rates of VF (plasma HIV RNA >200 copies/mL) were compared between those with and without PDR. Among 122 ARV-naive adults, PDR was detected by OLA in 17 (13.9%) adults. Compared with the 2007-2009 cohort, the proportion with PDR at OLA codons was significantly increased (p < .001). A total of 11 of 19 OLA mutations conferring high-level drug resistance were also detected by CS, and 8 additional participants had mutations encoding low-level resistance detected by CS for a total of 25 participants (20.5%). VF at month 6 of NNRTI-ART appeared greater in participants with versus without PDR [4/18 (22.2%) vs. 3/71 (4.2%); p = .03]. An increasing prevalence of PDR was detected among ARV-naive Peruvians. Studies are needed to determine risks of specific PDR mutations. SN - 1931-8405 UR - https://www.unboundmedicine.com/medline/citation/30560685/Pretreatment_HIV_Drug_Resistance_and_Virologic_Outcomes_to_First_Line_Antiretroviral_Therapy_in_Peru_ L2 - https://www.liebertpub.com/doi/full/10.1089/AID.2018.0239?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -